↓ Skip to main content

Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer

Overview of attention for article published in European Urology, June 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
7 X users
googleplus
1 Google+ user

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer
Published in
European Urology, June 2014
DOI 10.1016/j.eururo.2014.05.037
Pubmed ID
Authors

Laurent Boccon-Gibod, Peter Albers, Juan Morote, Hendrik van Poppel, Jean de la Rosette, Arnauld Villers, Anders Malmberg, Anders Neijber, Francesco Montorsi

Abstract

Guidelines for prostate cancer treatment suggest that intermittent androgen deprivation (IAD) can be considered for certain patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 3%
Unknown 38 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 15%
Researcher 5 13%
Professor 5 13%
Other 4 10%
Student > Bachelor 4 10%
Other 8 21%
Unknown 7 18%
Readers by discipline Count As %
Medicine and Dentistry 16 41%
Agricultural and Biological Sciences 4 10%
Engineering 2 5%
Computer Science 2 5%
Business, Management and Accounting 1 3%
Other 3 8%
Unknown 11 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2014.
All research outputs
#6,847,956
of 25,374,647 outputs
Outputs from European Urology
#3,193
of 6,216 outputs
Outputs of similar age
#61,364
of 242,959 outputs
Outputs of similar age from European Urology
#49
of 101 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 6,216 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.1. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,959 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.